{"id":"bendamustine-plus-rituximab","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Infection"},{"rate":"10-20","effect":"Infusion reactions"},{"rate":"20-30","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bendamustine is an alkylating agent that cross-links DNA and induces apoptosis in rapidly dividing cells. Rituximab is a chimeric monoclonal antibody against CD20, a surface antigen on B cells, which mediates antibody-dependent cellular cytotoxicity and direct cell death. The combination leverages chemotherapy cytotoxicity with targeted immunotherapy to improve efficacy in B-cell malignancies.","oneSentence":"Bendamustine chemotherapy damages cancer cell DNA while rituximab targets CD20 on B cells to enhance immune destruction of lymphoma cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:55.748Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma"},{"name":"Chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT01886872","phase":"PHASE3","title":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-15","conditions":"Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia","enrollment":547},{"nctId":"NCT07139873","phase":"PHASE3","title":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","status":"RECRUITING","sponsor":"Dizal (Jiangsu) Pharmaceutical Co., Ltd.","startDate":"2025-09-08","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":250},{"nctId":"NCT07492407","phase":"","title":"CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-04","conditions":"MZL","enrollment":131},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT04115631","phase":"PHASE2","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-12-13","conditions":"Liver Lymphoma, Mantle Cell Lymphoma","enrollment":360},{"nctId":"NCT01479842","phase":"PHASE1","title":"Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kami Maddocks, MD","startDate":"2014-03-26","conditions":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma","enrollment":48},{"nctId":"NCT06846671","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-04-10","conditions":"CLL, Chronic Lymphocytic Leukemia","enrollment":250},{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":"Untreated Follicular Lymphoma","enrollment":1018},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT05624554","phase":"PHASE3","title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-16","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":300},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT03336333","phase":"PHASE3","title":"A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2017-10-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":590},{"nctId":"NCT04285567","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-05-28","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":166},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT06084936","phase":"PHASE3","title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-10-22","conditions":"Lymphoma","enrollment":182},{"nctId":"NCT06504940","phase":"PHASE2","title":"Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-28","conditions":"Marginal Zone Lymphoma","enrollment":69},{"nctId":"NCT03609593","phase":"PHASE2","title":"Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Nicole Lamanna","startDate":"2018-11-12","conditions":"Chronic Lymphocytic Leukemia","enrollment":42},{"nctId":"NCT06854003","phase":"PHASE2","title":"BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2025-04-22","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":60},{"nctId":"NCT02972840","phase":"PHASE3","title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-04-05","conditions":"Lymphoma, Mantle Cell","enrollment":635},{"nctId":"NCT05551936","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaishalee Kenkre","startDate":"2023-01-26","conditions":"Follicular Lymphoma","enrollment":42},{"nctId":"NCT02970318","phase":"PHASE3","title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-02-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":310},{"nctId":"NCT04624906","phase":"PHASE2","title":"Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-03-02","conditions":"Waldenstrom Macroglobulinemia","enrollment":63},{"nctId":"NCT05023980","phase":"PHASE3","title":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-09-23","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":309},{"nctId":"NCT02717624","phase":"PHASE1","title":"A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2016-04-20","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":72},{"nctId":"NCT04022239","phase":"PHASE1, PHASE2","title":"Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-03-13","conditions":"Hematopoietic and Lymphoid System Neoplasm","enrollment":25},{"nctId":"NCT06425302","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-08-30","conditions":"Lymphoma, Follicular","enrollment":90},{"nctId":"NCT06970743","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-05-29","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":150},{"nctId":"NCT05249959","phase":"PHASE2","title":"Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2022-03-21","conditions":"Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":49},{"nctId":"NCT05816850","phase":"","title":"Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2023-09-19","conditions":"Follicular Lymphoma","enrollment":654},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":"Marginal Zone Lymphoma","enrollment":260},{"nctId":"NCT07189065","phase":"PHASE2","title":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2025-11-27","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":150},{"nctId":"NCT03567876","phase":"PHASE2","title":"Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2018-09-03","conditions":"Lymphoma, Mantle-Cell","enrollment":141},{"nctId":"NCT06911502","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-07-28","conditions":"Follicular Lymphoma","enrollment":400},{"nctId":"NCT03352765","phase":"PHASE1","title":"A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-11-20","conditions":"Lymphoma","enrollment":28},{"nctId":"NCT07259122","phase":"PHASE2","title":"A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-30","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":43},{"nctId":"NCT06561347","phase":"PHASE2","title":"Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-12-20","conditions":"Waldenstrom Macroglobulinemia","enrollment":55},{"nctId":"NCT03856216","phase":"PHASE2","title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-28","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm","enrollment":15},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT07208981","phase":"PHASE2","title":"Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-14","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":169},{"nctId":"NCT04607772","phase":"PHASE1, PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT04002297","phase":"PHASE3","title":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2019-08-20","conditions":"Mantle Cell Lymphoma; Non-Hodgkin Lymphoma","enrollment":510},{"nctId":"NCT01650701","phase":"PHASE3","title":"A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2012-02","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT07169565","phase":"PHASE1","title":"Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-01","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":21},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT07059650","phase":"PHASE1, PHASE2","title":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2025-08-19","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":150},{"nctId":"NCT05950334","phase":"PHASE1","title":"FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)","status":"COMPLETED","sponsor":"Fate Therapeutics","startDate":"2023-11-16","conditions":"Relapsed/Refractory B-Cell Lymphoma","enrollment":20},{"nctId":"NCT03424122","phase":"PHASE1","title":"INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2018-07-02","conditions":"B-cell Lymphoma","enrollment":50},{"nctId":"NCT03834688","phase":"PHASE2","title":"Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age","status":"COMPLETED","sponsor":"PrECOG, LLC.","startDate":"2020-01-13","conditions":"Mantle Cell Lymphoma","enrollment":33},{"nctId":"NCT04433182","phase":"PHASE2","title":"Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2020-08-18","conditions":"Diffuse Large B-cell Lymphoma","enrollment":37},{"nctId":"NCT02763319","phase":"PHASE2, PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-11-28","conditions":"Diffuse Large B-cell Lymphoma","enrollment":453},{"nctId":"NCT01776840","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-05-16","conditions":"Mantle Cell Lymphoma","enrollment":523},{"nctId":"NCT05025423","phase":"PHASE2","title":"Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-06-21","conditions":"Mantle Cell Lymphoma","enrollment":7},{"nctId":"NCT01059786","phase":"PHASE2","title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-01","conditions":"Hairy Cell Leukemia","enrollment":69},{"nctId":"NCT04673617","phase":"PHASE1, PHASE2","title":"AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Artiva Biotherapeutics, Inc.","startDate":"2021-03-29","conditions":"Non Hodgkin Lymphoma","enrollment":45},{"nctId":"NCT02414022","phase":"","title":"Economic Analysis of Alliance A041202 CLL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-04-15","conditions":"Chronic Lymphocytic Leukemia","enrollment":55},{"nctId":"NCT07008053","phase":"PHASE2","title":"BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-07","conditions":"Marginal Zone Lymphomas","enrollment":37},{"nctId":"NCT01974440","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-31","conditions":"Lymphoma","enrollment":403},{"nctId":"NCT01476787","phase":"PHASE3","title":"Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2011-12-29","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT03295240","phase":"EARLY_PHASE1","title":"The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-20","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":10},{"nctId":"NCT03623373","phase":"PHASE2","title":"Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-11-29","conditions":"Mantle Cell Lymphoma","enrollment":13},{"nctId":"NCT06942507","phase":"NA","title":"Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-05-01","conditions":"Waldenström's Macroglobulinemia (WM)","enrollment":104},{"nctId":"NCT04666038","phase":"PHASE3","title":"Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-03-09","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":238},{"nctId":"NCT01661881","phase":"PHASE2","title":"Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-08-16","conditions":"Mantle Cell Lymphoma","enrollment":23},{"nctId":"NCT01415752","phase":"PHASE2","title":"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2012-08-09","conditions":"Lymphoma, Mantle Cell Lymphoma","enrollment":373},{"nctId":"NCT06734078","phase":"","title":"An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2021-05-20","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":100},{"nctId":"NCT06557330","phase":"PHASE2","title":"MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2025-06","conditions":"Lymphoma, Indolent Non-hodgkin Lymphoma","enrollment":24},{"nctId":"NCT00769522","phase":"PHASE3","title":"FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2008-10-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":564},{"nctId":"NCT02950051","phase":"PHASE3","title":"Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2016-12-13","conditions":"Chronic Lymphocytic Leukemia","enrollment":926},{"nctId":"NCT03836261","phase":"PHASE3","title":"Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2019-02-25","conditions":"Chronic Lymphocytic Leukemia","enrollment":984},{"nctId":"NCT06363994","phase":"PHASE3","title":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL","status":"RECRUITING","sponsor":"InnoCare Pharma Inc.","startDate":"2024-05-29","conditions":"Mantle Cell Lymphoma","enrollment":476},{"nctId":"NCT03997968","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cyteir Therapeutics, Inc.","startDate":"2019-10-09","conditions":"Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma","enrollment":169},{"nctId":"NCT02626455","phase":"PHASE3","title":"Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-01-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":551},{"nctId":"NCT03524235","phase":"PHASE1","title":"Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL","status":"COMPLETED","sponsor":"Noah Merin","startDate":"2018-07-18","conditions":"Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia","enrollment":20},{"nctId":"NCT04745832","phase":"PHASE3","title":"Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)","status":"TERMINATED","sponsor":"MEI Pharma, Inc.","startDate":"2021-08-13","conditions":"Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma","enrollment":82},{"nctId":"NCT03311126","phase":"PHASE2","title":"Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2017-09-29","conditions":"Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma","enrollment":21},{"nctId":"NCT06284122","phase":"PHASE3","title":"Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2024-06-07","conditions":"Follicular Lymphoma","enrollment":790},{"nctId":"NCT05914662","phase":"PHASE2","title":"Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-02-15","conditions":"Waldenstrom Macroglobulinemia","enrollment":42},{"nctId":"NCT01456351","phase":"PHASE3","title":"Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2003-09","conditions":"Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma","enrollment":230},{"nctId":"NCT00991211","phase":"PHASE3","title":"Bendamustine Plus Rituximab Versus CHOP Plus Rituximab","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2004-01","conditions":"Non-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas","enrollment":549},{"nctId":"NCT00877214","phase":"PHASE3","title":"Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jurgen Barth","startDate":"2009-04-01","conditions":"Follicular Lymphomas, Immunocytomas, Marginal Zone Lymphomas","enrollment":1272},{"nctId":"NCT06554600","phase":"PHASE2","title":"A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-31","conditions":"Refractory or Relapsed Diffuse Large B Cell Lymphoma","enrollment":36},{"nctId":"NCT05245656","phase":"PHASE2","title":"A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma","status":"RECRUITING","sponsor":"Kim, Seok Jin","startDate":"2022-10-18","conditions":"Mantle Cell Lymphoma","enrollment":90},{"nctId":"NCT01664910","phase":"PHASE1, PHASE2","title":"CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-29","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":27},{"nctId":"NCT06496308","phase":"PHASE3","title":"Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-07-10","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":78},{"nctId":"NCT06482684","phase":"PHASE2","title":"CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma","status":"RECRUITING","sponsor":"Christian Schmidt, MD","startDate":"2024-02-15","conditions":"Mantle Cell Lymphoma","enrollment":150},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT05868395","phase":"PHASE2","title":"Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-01-02","conditions":"Mantle-cell Lymphoma","enrollment":16},{"nctId":"NCT04049825","phase":"PHASE1","title":"A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2019-11-22","conditions":"Relapsed or Refractory Diffuse Large B-cell Lymphoma","enrollment":36},{"nctId":"NCT06205290","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-01-16","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":""},{"nctId":"NCT06136351","phase":"PHASE2","title":"A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-11-15","conditions":"Lymphoma, Mantle-Cell","enrollment":23},{"nctId":"NCT05848765","phase":"PHASE2","title":"Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2023-09-04","conditions":"Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":284},{"nctId":"NCT03900377","phase":"PHASE1, PHASE2","title":"Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma","status":"COMPLETED","sponsor":"SymBio Pharmaceuticals","startDate":"2019-04-01","conditions":"Lymphoma, B-cell, Diffuse","enrollment":37},{"nctId":"NCT02733042","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-05-11","conditions":"Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":106},{"nctId":"NCT02728531","phase":"PHASE1","title":"Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04-18","conditions":"Mantle Cell Lymphoma","enrollment":18},{"nctId":"NCT04245722","phase":"PHASE1","title":"FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies","status":"TERMINATED","sponsor":"Fate Therapeutics","startDate":"2020-03-19","conditions":"Lymphoma, B-Cell, Chronic Lymphocytic Leukemia","enrollment":98},{"nctId":"NCT04023071","phase":"PHASE1","title":"FT516 in Subjects With Advanced Hematologic Malignancies","status":"TERMINATED","sponsor":"Fate Therapeutics","startDate":"2019-10-04","conditions":"Acute Myelogenous Leukemia, B-cell Lymphoma","enrollment":72},{"nctId":"NCT02005471","phase":"PHASE3","title":"A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-17","conditions":"Chronic Lymphocytic Leukemia","enrollment":389},{"nctId":"NCT05979948","phase":"PHASE2","title":"A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2023-08-01","conditions":"Waldenström's Macroglobulinemia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":148,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bendamustine plus Rituximab","genericName":"Bendamustine plus Rituximab","companyName":"University of Giessen","companyId":"university-of-giessen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bendamustine chemotherapy damages cancer cell DNA while rituximab targets CD20 on B cells to enhance immune destruction of lymphoma cells. Used for B-cell non-Hodgkin lymphoma, Chronic lymphocytic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}